QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:DFFN

Diffusion Pharmaceuticals Stock Forecast, Price & News

$0.27
-0.02 (-6.99%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.26
$0.30
50-Day Range
$0.27
$0.44
52-Week Range
$0.26
$1.85
Volume
520,794 shs
Average Volume
735,045 shs
Market Capitalization
$27.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
30 days | 90 days | 365 days | Advanced Chart
Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Diffusion Pharmaceuticals logo

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Headlines

DFFN: TSC to be Developed for Treatment of Hypoxic Tumors…
November 29, 2021 |  finance.yahoo.com
Diffusion Pharmaceuticals Issues Letter to Shareholders
September 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DFFN
Employees
14
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.39 per share

Profitability

Net Income
$-14.19 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
100,493,000
Market Cap
$27.12 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/18/2022
Next Earnings (Estimated)
3/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.13 out of 5 stars

Medical Sector

1226th out of 1,414 stocks

Pharmaceutical Preparations Industry

589th out of 682 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

Is Diffusion Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Diffusion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DFFN, but not buy additional shares or sell existing shares.
View analyst ratings for Diffusion Pharmaceuticals
or view top-rated stocks.

How has Diffusion Pharmaceuticals' stock price been impacted by COVID-19?

Diffusion Pharmaceuticals' stock was trading at $0.3434 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DFFN stock has decreased by 22.5% and is now trading at $0.2661.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 943,000 shares, an increase of 107.6% from the November 30th total of 454,200 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.9% of the company's shares are sold short.
View Diffusion Pharmaceuticals' Short Interest
.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Diffusion Pharmaceuticals
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.08.
View Diffusion Pharmaceuticals' earnings history
.

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Shares of Diffusion Pharmaceuticals reverse split on the morning of Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the following people:
  • Robert J. Cobuzzi, President, Chief Executive Officer & Director
  • William Hornung, Chief Financial Officer
  • Christopher D. Galloway, Chief Medical Officer
  • Harry N. Cook, Vice President-Clinical Operations
  • William R. Elder, Secretary & General Counsel

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $0.27.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals has a market capitalization of $27.12 million. The company earns $-14.19 million in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does Diffusion Pharmaceuticals have?

Diffusion Pharmaceuticals employs 14 workers across the globe.

What is Diffusion Pharmaceuticals' official website?

The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com.

Where are Diffusion Pharmaceuticals' headquarters?

Diffusion Pharmaceuticals is headquartered at 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at (434) 220-0718, via email at [email protected], or via fax at 434-220-0722.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.